

## Supplementary Appendix Figure 1 Study flow diagram




## Supplementary Appendix Figure 2. Base line characteristics

Study ID, setting, trial registration no.	Intervention drug & dosage	Outcomes				
	Warfarin	Number randomised (% male)	Age, years mean (SD)	CHADS₂ score ≥ 3 (n, %)		
Factor Xa Phase III trials						
ARISTOTLE (Granger 2011 * other secondary reports) 39 countries;	Apixaban 5mg x 2/day	9210 (65%)	*70 (63-76)	2758 (30%)	Primary: stroke, systemic embolism, major bleeding Secondary: all-cause mortality, MI, an bleeding, liver function abnormalities,	
NCT00412984	2mg target INR 2.0-3.0	9081 (65%)	* 70 (63-76)	2744 (30%)	other AEs	
ENGAGE AF-TIMI 48 Giugliano 2013 46 countries; NCT00781391	Edoxaban 60mg Edoxaban 30mg Dose halved in both groups for pts < 60kg or creatinine clearance of 30-50ml per minute or use of verapamil/quinidine	4366 (62.1%) 4304 (61.2%)	*72 (64-78) *72 (64-78)	Mean (SD) 2.8 (1) Mean (SD) 2.8 (1)	Primary: stroke, systemic embolism, major bleeding Secondary: MI, all-cause mortality	
	Target INR 2.0-3.0	4395 (62.5%)	*72 (64-78)	Mean (SD) 2.8 (1)		
Rocket-AF Patel 2011 45 countries; NCT00403767	Rivaroxaban20mg (15mg in patients with creatinine clearance of 30- 49ml per minute) Target INR 2-3	7131 (61%) 7133 (60%)	*73 (65-78)	6205 (87%)	Primary: Stroke or systemic embolism Secondary Ischaemic stroke, intracranial haemorrhage, major bleeding, gastrointestinal bleeding, MI, all-cause mortality	
J-Rocket AF	Rivaroxaban 15mg	639 (83%)	**71.0 (34-89)	542 84.8%	Primary: Stroke or systemic embolic	
Hori 2012 Japan; NCT00494871	Target INR 2-3 {1.6-2.6 if ≥ 70 years}	639 (78%)	**71.2 (43-90)	524 82.0%	event Secondary: Ischaemic stroke, haemorrhagic stroke, systemic embolism, vascular death, mortality, myocardial infarction, major bleeding, gastrointestinal bleeding, clinically relevant non-major bleeding	
Factor IIa Phase III trials						
RE-LY Connolly 2009 + 5 secondary reports; 44	Dabigatran 110mg x 2/day Dabigatran 150mg x 2/day	6015 6075	71.4 (8.6) 71.5 (8.8)	1968 (33%) 1981 (33%)	Primary: Stroke or systemic embolism Secondary: haemorrhagic stroke,	
countries; NCT00262600	1, 3 or 5mg, target INR 2.0- 3.0	6022	71.6 (8.6)	1933 (32%)	all-cause mortality	
Factor Xa Phase II trials						
Ogawa 2011 Ap Japan; NCT00787150 Tai	Apixaban 2.5mg x 2/day Apixaban 5mg x 2/day Target INR 2.0-3.0	74 (85%) 74 (82%) 74 (81%)	*69.3 70.0 71.7	17 (23%) 23 (31%) 21 (28%)	Primary: Composite of major bleedir and clinically relevant non-major bleeding Secondary: Ischaemic stroke, system embolism, MI, all-cause mortality	
	(1.6-2.6 if ≥ 70 years)	ra (oxa)	15500	er (row)		
Edoxaban Asia Chung 2011 Taiwan, Singapore,	Edoxaban 30mg x 4/day Edoxaban 60mg x 4/day	79 (65%) 80 (69%)	64.9 (9.1) 65.9 (7.7)	22 (27.8%) 22 (27.5%)	Primary: Major or clinically relevant, but non-major bleeding	
Hong Kong, South Korea; NCT00504556	Target INR 2.0	75 (62%)	64.5 (9.5)	17 (22.7%)	Secondary: Ischaemic stroke, systemic embolism, MI, all-cause mortality	
Edoxaban Japan Yamashita 2012 Japan; No clinical trial registration identified. No reply from authors.	Edoxaban 30mg Edoxaban 45mg Edoxaban 60mg Target INR 2.0-3.0	110 (84.0%) 109 (81.3%) 107 (81.7%) 107 (82.9%)	69.4 69.5 68.4 68.8	mean/median 1.9/2 mean/median 2.1/2 mean/median 2.1/2 mean/median 2.2/2	Primary: all bleeding Secondary: thromboembolic events	
Edoxaban US/Europe Weitz 2010 USA, eastern Europe; NCT00504556	Edoxaban 30mg Edoxaban 30mg x 2/day Edoxaban 60mg Edoxaban 60mg x 2/day	235 (60%) 245 (61%) 23 (66%). 180 (63%)	65.2 (8.3) 64.8 (8.8) 64.9 (8.8) 64.7 (9.0)	87 88 87 67	Primary: Major or clinically relevant, but non-major bleeding Secondary: Ischaemic stroke, haemorrhagic stroke, systemic embolism, MI, all-cause mortality	
	Target INR 2-0	251 (60%)	66.0 (8.5)	90	constantly only an earlier mortality	
Explore-Xa (Connolly 2013 + other secondary reports)	Betrixaban 40mg Betrixaban 60mg Betrixaban 80mg	127 (62%) 127 (64%) 127 (70%)	73.3 (8.50) 73.8 (8.35) 72.0 (7.65)	47 (37.0) 46 (36.2) 29 (23%)	Primary: Major or clinically relevant, but non-major bleeding Secondary: Ischaemic stroke, haemorrhagic stroke, systemic	
USA, Canada, Germany; NCT00742859	Target INR 2-0	127 (70%)	72.7 (8.75)	48 (38%)	embolism, MI, all-cause mortality.	
Turpie 2010  DPAL-1  lapan, Singapore,  Malaysia, Taiwan,  Korea, Hong Kong, New  Zealand, Thailand,  South Africa;  NCT00448214	YM150 30mg YM150 60mg YM150 120mg YM150 120mg YM150 240mg Target INR 2-0 1, 3 or 5mg, target INR 2.0- 3.0	90 (86%) 93 (76%) 93 (80%) 78 (77%) 94 (77%)	69.3 (8.4) 68.4 (9.4) 67.0 (9.6) 67.4 (9.0) 67.0 (9.4) 71.6 (8.6)	21 (23.3%) 19 (20.4%) 24 (25.8%) 18 (23.1%) 17 (18.1%)	Primary: Major or clinically relevant, but non-major bleeding Secondary: Ischaemic stroke, haemorrhagic stroke, systemic embolism, MI, all-cause mortality	
Factor IIa Phase II trials						
Lip 2009; Austria, Denmark, Hungary, Ireland Norway, Poland, Russia, Sweden, UK; NCT00684307	AZD0837 150mg once daily AZD0837 300mg once daily AZD0837 450mg once daily AZD0837 200mg twice daily	166 (71%) 152 (69%) 157 (69%) 161 (67%)	**69.9 (43-93 **69.8 (45-92) **69.3 (45-88) **67.8 (34-88)	NR	Primary: Major or clinically relevant, but non-major bleeding Secondary: Ischaemic stroke, haemorrhagic stroke, systemic	
	Target INR 2-0	319 (68%)	**68.3 (33-87)	NR	embolism, MI, all-cause mortality	

### Supplementary Appendix Figure 3 Risk of Bias Summary Table One




## Supplementary Appendix Figure 4 Risk of Bias Summary Table Two




# Supplementary Appendix Figure 5 Stroke or Systemic Embolism Fixed Effects Model

	Novel Oral Antico	agulant	Warfa	arin.		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
1.1.1 Phase III Trials of Facto	r Xa Inhibitors						
ARISTOTLE 2011	212	9210	265	9081	20.5%	0.78 [0.65, 0.94]	o <del>, </del>
ROCKETAF 2011	269	7081	306	7090	23.1%	0.88 [0.74, 1.03]	-
ENGAGE 2013 Edoxaban 30	383	7034	168	3518	16.6%	1.15 [0.95, 1.38]	+-
ENGAGE 2013 Edoxaban 60	296	7035	169	3518	17.0%	0.87 [0.72, 1.06]	-
J-Rocket AF 2012	11	637	22	637	1.7%	0.49 [0.24, 1.02]	-
Subtotal (95% CI)		30997		23844	78.9%	0.90 [0.82, 0.98]	•
Total events	1171		930				
Heterogeneity: Chi <sup>z</sup> = 11.62, dt Test for overall effect: $Z = 2.31$		6%					
1.1.2 Phase III Trials of Direct	Thrombin (Factor I	la) Inhibito	ors				
RE-LY 2009 Dabigatran 110	183	6015	101	3011	10.3%	0.90 [0.71, 1.16]	
RE-LY 2009 Dabigatran 150	134	6076	101	3011	10.4%	0.65 [0.50, 0.84]	
Subtotal (95% CI)		12091		6022	20.6%	0.78 [0.65, 0.93]	
Total events	317		202				
Heterogeneity: Chi <sup>2</sup> = 3.23, df = Test for overall effect: Z = 2.77		%					
1.1.3 Phase II Trials of Factor	Xa Inhibitors						
Edoxaban US/Europe 2010	6	893	3	250	0.4%	0.56 [0.14, 2.24]	
OPAL-1 2010 - YM150	2	354	0	·	0.1%	1.34 [0.06, 28.16]	
Subtotal (95% CI)		1247		344	0.4%	0.67 [0.19, 2.34]	
Total events	8		3				
Heterogeneity: Chi <sup>z</sup> = 0.27, df = Test for overall effect: Z = 0.63		·					
1.1.4 Phase II Trials of Direct	Thrombin (Factor II	a) Inhibito	rs				
Lip 2009 - AZD0837	2	631	0		0.1%	2.53 [0.12, 52.85]	701 - 04 - 707 - 90 T - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
Subtotal (95% CI)		631		318	0.1%	2.53 [0.12, 52.85]	
Total events	2		0				
Heterogeneity: Not applicable Test for overall effect: Z = 0.60	(P = 0.55)						
Total (95% CI)		44966		30528	100.0%	0.87 [0.81, 0.95]	•
Total events	1498		1135				
Heterogeneity: Chiz = 17.95, dt	$= 9 (P = 0.04); I^2 = 50$	0%					
Test for overall effect: Z = 3.30							0.1 0.2 0.5 1 2 5 10 Favours NOA Favours Warfarin
Test for subgroup differences:		= 0.43), l <sup>2</sup>	= 0%				ravours NOA Favours Warrann

### Supplementary Appendix Figure 6 Ischaemic Stroke Fixed Effects Model



### Supplementary Appendix Figure 7




# Supplementary Appendix Figure 8 Major or Clinically Relevant Non-Major Bleeding Random Effects Forest Plot

	Novel Oral Antic	oagulant	Warfa	rin		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	<b>Events</b>	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.5.1 Phase III Trials of Facto	r Xa Inhibitors						26
ARISTOTLE 2011	613	9088	877	9052	16.7%	0.67 [0.61, 0.75]	•
ROCKETAF 2011	1475	7111	1449	7125	17.0%	1.03 [0.95, 1.11]	
ENGAGE 2013 Edoxaban 30	1161	7002	880	3506	16.8%	0.59 [0.54, 0.65]	<u> </u>
ENGAGE 2013 Edoxaban 60	1528	7012	881	3506	16.9%	0.83 [0.75, 0.91]	_
J-Rocket AF 2012	138	639	124	639	13.5%	1.14 [0.87, 1.50]	+
Subtotal (95% CI)		30852		23828	80.9%	0.82 [0.65, 1.03]	•
Fotal events	4915		4211				
Heterogeneity: Tau <sup>z</sup> = 0.06; Ch	i <sup>2</sup> = 87.77, df = 4 (P	< 0.00001);	$I^2 = 95\%$				
Fest for overall effect: $Z = 1.73$	(P = 0.08)						
1.5.2 Phase III Trials of Direct	Thrombin (Factor	lla) Inhibito	ors				
Subtotal (95% CI)		0		0		Not estimable	
Fotal events	0		0				
Heterogeneity: Not applicable							
Fest for overall effect: Not appl	icable						
1.5.3 Phase II Trials of Factor	Xa Inhibitors						
ARISTOTLE-J 2011	2	143	4	75	1.4%	0.25 [0.05, 1.41]	
Edoxaban Asia 2011	6	159	5	75	2.5%	0.55 [0.16, 1.86]	-
Edoxaban US/Europe 2010	54	893	8	250	5.3%	1.95 [0.91, 4.15]	+-
ExploreXa 2013 Betrixaban	11	381	7	127	3.7%	0.51 [0.19, 1.34]	
OPAL-1 2010 - YM150	20	354	2	94	1.8%	2.75 [0.63, 12.00]	<del></del>
Subtotal (95% CI)		1930		621	14.6%	0.89 [0.39, 2.03]	•
Fotal events	93		26				
Heterogeneity: Tau² = 0.52; Ch Test for overall effect: Z = 0.29		= 0.04);  2=	61%				
1.5.4 Phase II Trials of Direct	Thrombin (Factor I	la) Inhibito	rs				
Lip 2009 - AZD0837	14	631	9	318	4.5%	0.78 [0.33, 1.82]	
Subtotal (95% CI)		631		318	4.5%	0.78 [0.33, 1.82]	•
Fotal events	14		9				
Heterogeneity: Not applicable							
Fest for overall effect: $Z = 0.58$	(P = 0.56)						
otal (95% CI)		33413		24767	100.0%	0.84 [0.68, 1.03]	
Fotal events	5022		4246				200
Heterogeneity: Tau² = 0.06; Ch	i²= 98.72, df= 10 (F	< 0.00001	$); 1^2 = 90^9$	%			0.01 0.1 1 10 10
Test for overall effect: $Z = 1.68$	(P = 0.09)						Favours NOA Favours Warfari
Test for subgroup differences:	$Chi^2 = 0.05, df = 2$ (F	$l = 0.98$ ), $l^2$	= 0%				ravous ivon Tavous Vidilal


# Supplementary Appendix Figure 9 Major Bleeding Fixed Effects Model Forest Plot

	Novel Oral Antico	agulant	Warfa	vrin.		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
1.6.1 Phase III Trials of Facto	r Xa Inhibitors						3
ARISTOTLE 2011	327	9088	462	9052	21.9%	0.69 [0.60, 0.80]	
ROCKETAF 2011	395	7111	386	7125	17.8%	1.03 [0.89, 1.19]	-
ENGAGE 2013 Edoxaban 30	254	7002	262	3506	16.5%	0.47 [0.39, 0.56]	-
ENGAGE 2013 Edoxaban 60	418	7012	262	3506	16.1%	0.78 [0.67, 0.92]	-
J-Rocket AF 2012	19	639	23	639	1.1%	0.82 [0.44, 1.52]	-
Subtotal (95% CI)		30852		23828	73.4%	0.75 [0.69, 0.80]	1
Total events	1413		1395				
Heterogeneity: Chi≅= 47.22, dt Test for overall effect: Z = 7.50	30:010 - 11:100:00:10 16:00 00:00	²= 92%					
1.6.2 Phase III Trials of Direct	t Thrombin (Factor I	lla) Inhibito	ors				
RE-LY 2009 Dabigatran 110	342	6015	211	3011	13.0%	0.80 [0.67, 0.96]	-
RE-LY 2009 Dabigatran 150	399	6076	210	3011	12.9%	0.94 [0.79, 1.11]	-
Subtotal (95% CI)		12091		6022	25.8%	0.87 [0.77, 0.98]	•
Total events	741		421				
Heterogeneity: Chi <sup>2</sup> = 1.57, df =	$= 1 (P = 0.21); I^2 = 36$	6%					
Fest for overall effect: $Z = 2.23$	(P = 0.03)						
I.6.3 Phase II Trials of Factor	Xa Inhibitors						
Edoxaban Asia 2011	0	159	2	75	0.2%	0.09 [0.00, 1.94]	+
Edoxaban US/Europe 2010	12	893	1	250	0.1%	3.39 [0.44, 26.21]	5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Edoaban Japan 2012	5	394	0	125	0.0%	3.54 [0.19, 64.55]	<del>-   .</del>
ExploreXa 2013 Betrixaban	3	381	5	127	0.4%	0.19 [0.05, 0.82]	
DPAL-1 2010 - YM150	1	354	0	94	0.0%	0.80 [0.03, 19.85]	
Subtotal (95% CI)		2181		671	0.7%	0.74 [0.34, 1.60]	•
Fotal events	21		8				
Heterogeneity: Chi² = 8.34, df : Fest for overall effect: Z = 0.77		2%					
1.6.4 Phase II Trials of Direct	Thrombin (Factor II	la) Inhibito	rs				
Lip 2009 - AZD0837	5	631	2	318	0.1%	1.26 [0.24, 6.54]	
Subtotal (95% CI)		631		318	0.1%	1.26 [0.24, 6.54]	
Fotal events	5		2				
Heterogeneity: Not applicable							
Test for overall effect: $Z = 0.28$	(P = 0.78)						
fotal (95% CI)		45755		30839	100.0%	0.78 [0.73, 0.83]	1
Fotal events	2180		1826				
Heterogeneity: Chi² = 61.98, dt	<ul> <li>screpentation the problem was not as and</li> </ul>	I <sup>2</sup> = 81%					La
est for overall effect: Z = 7.59							0.01 0.1 1 10 10
est for subgroup differences:	311.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	= 0.21) 12	= 34 2%				Favours NOA Favours Warfar



Supplementary Appendix Figure 10 Major Bleeding Random Effects Model

### Supplementary Appendix Figure 11 Gastrointestinal Bleeding Fixed Effects Model Forest Plot



# Supplementary Appendix Figure 12 Gastrointestinal Bleeding Random Effects Model Forest Plot

	Novel Oral Antic	agulant	Warfa	rin.		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	<b>Events</b>	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.7.1 Phase III Trials of Factor X	a Inhibitors						34
ARISTOTLE 2011	105	9088	119	9052	15.7%	0.88 [0.67, 1.14]	t <del>de</del> g
ROCKETAF 2011	224	7111	154	7125	16.8%	1.47 [1.20, 1.81]	
ENGAGE 2013 Edoxaban 30	129	7002	95	3506	15.7%	0.67 [0.52, 0.88]	-
ENGAGE 2013 Edoxaban 60	232	7012	95	3506	16.2%	1.23 [0.96, 1.57]	-
J-Rocket AF 2012	7	639	15	639	5.6%	0.46 [0.19, 1.14]	-
Subtotal (95% CI)		30852		23828	70.0%	0.95 [0.68, 1.34]	•
Total events	697		478				
Heterogeneity: Tau² = 0.12; Chi² =	= 27.22, df = 4 (P	< 0.0001); I	<sup>2</sup> = 85%				
Fest for overall effect: Z = 0.29 (P	= 0.77)						
1.7.2 Phase III Trials of Direct T	hrombin (Factor	lla) Inhibito	ors				
RE-LY 2009 Dabigatran 110	133	6015	60	3011	14.8%	1.11 [0.82, 1.51]	( <del>     </del>
RE-LY 2009 Dabigatran 150	182	6076	60	3011	15.1%	1.52 [1.13, 2.04]	-
Subtotal (95% CI)		12091		6022	30.0%	1.30 [0.96, 1.77]	•
Fotal events	315		120				
Heterogeneity: Tau² = 0.02; Chi² =	= 2.05, df = 1 (P =	$0.15$ ); $I^2 = 9$	51%				
Test for overall effect: $Z = 1.70$ (P	= 0.09)						
1.7.3 Phase II Trials of Xa Inhibi	tors						
Subtotal (95% CI)		0		0		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Fest for overall effect: Not applica	ble						
1.7.4 Phase II Trials of Direct Th	rombin (Factor I	la) Inhibito	rs				
Subtotal (95% CI)	201 201 201 201 201 <b>3</b> 0 170 201 201 201 201	0		0		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable	_						
Test for overall effect: Not applica	ble						
Total (95% CI)		42943		29850	100.0%	1.05 [0.82, 1.36]	•
Total events	1012		598			este para la mario de se tratación de C	
Heterogeneity: Tau² = 0.09; Chi² =	STATE OF THE PARTY	< 0.00011:1	x vald5:5:5:5				
Test for overall effect: Z = 0.39 (P	ST 82-35-35-35	0.0001),1	0170				0.01 0.1 1 10 10
Test for subgroup differences: Ch		= 0.18) 12	= 45 3%				Favours NOA Favours Warfar

# Supplementary Appendix Figure 13 Myocardial Infarction Fixed Effects Model Forest Plot

	Novel Oral Anticoa	gulant	Warfa	rin		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	<b>Events</b>	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% CI
1.8.1 Phase III Trials of Facto	r Xa Inhibitors						1
ARISTOTLE 2011	90	9120	102	9081	19.8%	0.88 [0.66, 1.17]	-
ROCKET AF 2011	101	7061	126	7082	24.3%	0.80 [0.62, 1.04]	<del>-</del>
ENGAGE 2013 Edoxaban 30	169	7034	70	3518	17.8%	1.21 [0.92, 1.61]	<del> -</del>
ENGAGE 2013 Edoxaban 60	133	7035	71	3518	18.2%	0.94 [0.70, 1.25]	+
J-Rocket AF 2012	3	637	1	637	0.2%	3.01 [0.31, 29.01]	
Subtotal (95% CI)		30887		23836	80.3%	0.95 [0.82, 1.09]	•
Fotal events	496		370				
Heterogeneity: Chi <sup>z</sup> = 5.79, df =	= 4 (P = 0.22); I <sup>2</sup> = 31%						
Test for overall effect: $Z = 0.77$	(P = 0.44)						
1.8.2 Phase III Trials of Direct	Thrombin (Factor IIa	) Inhibite	ors				
RE-LY 2009 Dabigatran 110	98	6015	38	3011	9.8%	1.30 [0.89, 1.89]	+
RE-LY 2009 Dabigatran 150	97	6076	37	3011	9.5%	1.30 [0.89, 1.91]	<del> -</del>
Subtotal (95% CI)		12091		6022	19.3%	1.30 [0.99, 1.70]	₩
otal events	195		75				
Heterogeneity: Chi <sup>2</sup> = 0.00, df =	= 1 (P = 0.98); I <sup>2</sup> = 0%						
Test for overall effect: $Z = 1.92$	(P = 0.06)						
1.8.3 Phase II Trials of Factor	Xa Inhibitors						
Edoxaban US/Europe 2010	5	893	0	250	0.2%	3.10 [0.17, 56.28]	· · · · · · · · · · · · · · · · · · ·
Edoxaban Asia 2011	0	159	0	79		Not estimable	
Subtotal (95% CI)		1052		329	0.2%	3.10 [0.17, 56.28]	
Fotal events	5		0				
Heterogeneity: Not applicable							
est for overall effect: Z = 0.77	(P = 0.44)						
1.8.4 Phase II Trials of Direct	Thrombin (Factor IIa)	Inhibito	rs				
Lip 2009 - AZD0837	2	631	1	318	0.3%	1.01 [0.09, 11.16]	-
Subtotal (95% CI)		631		318	0.3%	1.01 [0.09, 11.16]	
Fotal events	2		1				
Heterogeneity: Not applicable							
Test for overall effect: $Z = 0.01$	(P = 0.99)						
otal (95% CI)		44661		30505	100.0%	1.02 [0.90, 1.15]	
otal events	698		446				
Heterogeneity: Chi² = 10.66, df	$f = 8 (P = 0.22);  F = 25^{\circ}$	<b>%</b>					100 01 10 10 10
Test for overall effect: $Z = 0.30$							0.01 0.1 1 10 10 Favours NOA Favours Warfari
est for subgroup differences:		0.19), I <sup>2</sup>	= 37.5%				rayours NOA Fayours Warrar

### Supplementary Appendix Figure 14 Myocardial Infarction Random Effects Model Forest Plot

